Chronic Lymphocytic Leukemia Treatment Market to Benefit from Rising Number of Cases

Pune, India, June 2022, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Chronic Lymphocytic Leukemia Treatment Market.

Market Scenario

The Chronic Lymphocytic Leukemia Treatment Market is expected to reach USD 8.68 Billion by 2030 at 8.52% CAGR during the forecast period 2023-2030

Market Drivers and Key Challenges

Chronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults. This type of cancer involves the development of lymphocytes, which are white blood cells, within the bone marrow. The lymphocytic leukemia cells are generally present in the lymph nodes along with various other tissues. There are two primary types of chronic lymphocytic leukemia, wherein one grows slowly, and the other is considered fatal. In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period. However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.

Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases. An article published by Apollo Hospitals states that in India, roughly one million cases of chronic lymphocytic leukemia are diagnosed annually. As per the cancer statistics, 1 in every 155 men and 1 in every 260 women get affected with CLL in their lifetime, in the United Kingdom (U.K). The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.

Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years. However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.

Market Segmentation

The global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.

The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.

The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.

The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Chronic Lymphocytic Leukemia Treatment Market Research Report

Prominent Players

The prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.

Regional Insight

The chronic lymphocytic leukemia treatment market is set to expand in the region of Europe, Asia Pacific, America, and the Middle East & Africa during the assessment period.

Following a meticulous analysis of the global trends, the Americas has been identified as the leading region in the chronic lymphocytic leukemia treatment market. The increasing prevalence of leukemia, as well as the presence of prominent vendors within the region, are the main factors responsible for the strong performance of the market. In 2018, a report published by the Leukemia & Lymphoma Society stated that every 3 minutes, an individual in the United States (US) gets diagnosed with blood cancer or leukemia.

Europe has managed to seize the second largest share of the global chronic lymphocytic leukemia treatment market. Sound healthcare infrastructure, massive healthcare spending, high awareness levels with regard to relapse of Chronic Lymphocytic Leukemia (CLL) as well as related treatments, availability of reimbursement policies, use of advanced healthcare tools and the growing adoption rate of latest techniques in practice are few lucrative factors steering the CLL treatment market towards greater heights.

With the hike in the research and development activities and the presence of profitable small markets like India, Japan, China, Australia, Republic of Korea, the Asia Pacific market is expected to expand further in the subsequent years. The region is also predicted to grow at the fastest rate, backed by factors like the growing prevalence of leukemia combined with the consequently surging demand for treatment of CLL in the region. The 2017 report furnished by the World Health Organization (WHO) suggests that at least 8,904 leukemia deaths have been reported in Japan that year, indicating the rising number of cases within the region.

The most abysmal performance has been showcased by the Middle East & Africa, having managed to acquire the least share of the worldwide market. However, the lukewarm growth of the market points towards better prospects in the future, owing to the expanding healthcare infrastructure.

Industry Developments

  • May 2019: Venetoclax (Venclexta, AbbVie, and Genentech) along with Obinutuzumab (Gazyva, Genentech) has been granted FDA approval for untreated chronic lymphocytic leukemia (CLL). Venclexta, as well as Gazyva, is considered to be the only chemotherapy-free option for providing favorable responses to aid the patients in living longer and curbing the progression of CLL as well.



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Report details
Base Year 2022
Companies Covered 15
Pages 90
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.